Treatment-resistant depression is not a category we treat at the margin. It is the patient population this practice was built for.
50–60% respond · ~40% remission
Gentle magnetic pulses stimulate underactive brain regions involved in mood regulation. FDA-approved for major depressive disorder and OCD in patients ages fifteen and up. A typical course runs across weekday sessions over several weeks at the Medical District location.
70% improvement · ~50% remission
Spravato is a nasal-spray esketamine treatment for treatment-resistant depression, administered on site under medical supervision per the FDA REMS protocol. A typical course begins with twice-weekly sessions tapering across the first two months.
A single cheek swab
GeneSight analyzes how a patient's genes affect medication metabolism, reducing trial-and-error in medication selection. Used at the practice both for new patients with no prior trials and for established patients whose current regimen is not working.
All three offered on site · Medical District for TMS and Spravato · Both locations for medication management and GeneSight
A typical PHQ-9 trajectory across a TMS course at Stillwater. The dashed line is the response threshold, where depression severity steps down out of moderate. Most patients cross it around week four.